Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Ivonescimab Receives Breakthrough Therapy Designation for IO-Resistant NSCLC in China

November 16th 2022

The Center for Drug Evaluation of the China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab plus docetaxel for patients with locally advanced or metastatic non–small cell lung cancer who failed to respond to a prior PD-(L)1 inhibitor plus platinum-based doublet chemotherapy.

A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

November 16th 2022

The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.

The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC

November 16th 2022

Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.

Dr. Halmos on Trastuzumab Deruxtecan in NSCLC

November 14th 2022

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations

November 14th 2022

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC

November 14th 2022

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

Osimertinib Remains the Preferred Frontline Choice for EGFR-Mutated NSCLC

November 14th 2022

Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.

Targeting the ‘New Kids on the Block’ in NSCLC: EGFR Exon 20 and MET Exon 14 Skipping Mutations

November 14th 2022

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13th 2022

CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.

Dr. Levy on the Future of Atezolizumab in NSCLC

November 11th 2022

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

Pembrolizumab/Eftilagimod alpha Combo Shows Durable Responses in Frontline NSCLC

November 11th 2022

The first-line combination of pembrolizumab and eftilagimod alpha elicited a 40.4% (95% CI, 31.3%-50.0%) overall response rate by immune RECIST criteria in the intent-to-treat population in patients with advanced non–small cell lung cancer, according to updated findings from the phase 2 TACTI-002 trial.

Dr. Halmos on the FDA Approval of Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC

November 11th 2022

Balazs Halmos, MD, discusses the significance of the FDA approval of tremelimumab-actl plus durvalumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. Kris on Atezolizumab in NSCLC

November 10th 2022

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

FDA Approves Tremelimumab Plus Durvalumab and Chemo for Metastatic NSCLC

November 10th 2022

The FDA has approved tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

The Future of Molecular Testing in NSCLC

November 9th 2022

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Financial Considerations with Molecular Testing for Patients With NSCLC

November 9th 2022

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.

The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC

November 9th 2022

Drs Peters and Velcheti provide an overview of the role of anti-TGIT immunotherapies in NSCLC treatment.

Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy

November 9th 2022

Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.

Exciting NSCLC Data Updates from ESMO 2022

November 9th 2022

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

FDA Approves Cemiplimab-rwlc Plus Platinum-based Chemotherapy for Advanced NSCLC

November 8th 2022

The FDA has approved cemiplimab-rwlc (Libtayo) in combination with platinum-based chemotherapy in adult patients with advanced non–small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.